The Butantan Biological Institute decided to officially end the manufacturing of the Sinovac coronavirus vaccine, sold under the brand name CoronaVac. Production had already been halted in October 2021, as the Brazilian vaccine rollout advanced and the use of other vaccines became more important.
Butantan says it hasn’t received new orders for vaccine jabs since February.
CoronaVac was the first vaccine administered in Brazil, in January 2021, and remained the country’s most-used jab until July of that year.
After that, it was surpassed by AstraZeneca, according to official data. The Sinovac vaccine remains the only vaccine administered in the country that has not been given a definitive registration by regulators, unlike the AstraZeneca, Janssen, and Pfizer jabs.
The last pack with over 110 million CoronaVac doses was sent from Butantan to the Brazilian Health Ministry in February. The biological institute says there is no forecast for production to be resumed.
The Ibre-FGV GDP monitor, a tool to predict economic activity in Brazil, suggests that the…
The floods in the Brazilian state of Rio Grande do Sul have killed nearly 150…
Home to the largest tropical forest in the world, an energy mix that is high…
The northeastern Brazilian state of Piauí isn’t among the country’s richest or most populous states…
Rio Grande do Sul Lieutenant-Governor Gabriel Souza said the state government is considering relocating entire…
“We’ve got no idea what the next vintage is going to look like. A lot…